Short Interest in Valneva SE Sponsored ADR (NASDAQ:VALN) Expands By 91.2%

Valneva SE Sponsored ADR (NASDAQ:VALN) saw a significant growth in short interest in July. As of July 31st, there was short interest totaling 45,500 shares, agrowthof91.2% from the July 15th total of 23,800 shares. Approximately0.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 52,800 shares, the short-interest ratio is presently 0.9 days. Based on an average daily trading volume, of 52,800 shares, the short-interest ratio is presently 0.9 days. Approximately0.1% of the shares of the stock are sold short.

Hedge Funds Weigh In On Valneva

Several hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN grew its position in shares of Valneva by 14.3% in the fourth quarter. Wells Fargo & Company MN now owns 246,766 shares of the company’s stock valued at $1,079,000 after purchasing an additional 30,859 shares during the period. GAMMA Investing LLC purchased a new stake in shares of Valneva in the first quarter valued at $94,000. Finally, Frazier Life Sciences Management L.P. purchased a new stake in shares of Valneva in the second quarter valued at $8,240,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva Stock Performance

Valneva stock opened at $11.53 on Monday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.77 and a current ratio of 2.27. The stock has a fifty day moving average of $6.86 and a two-hundred day moving average of $6.77. The company has a market capitalization of $981.09 million, a price-to-earnings ratio of -11.77 and a beta of 1.77. Valneva has a fifty-two week low of $3.62 and a fifty-two week high of $11.53.

Valneva (NASDAQ:VALN) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.11. The company had revenue of $54.84 million during the quarter, compared to the consensus estimate of $46.28 million. Valneva had a negative return on equity of 34.78% and a negative net margin of 33.87%. On average, analysts anticipate that Valneva will post 0.13 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Guggenheim dropped their price target on Valneva from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, May 8th.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.